Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results)
-
- Imagawa
- Creator
Journal
-
- Clin. Exp. Rheumatol.
-
Clin. Exp. Rheumatol. 31 302-, 2013
